Complete response to multidisciplinary therapy in a patient with primary gastric choriocarcinoma

Table 1 Review of the English and Japanese literature for cases of recurrent or unresectable primary gastric choriocarcinoma treated with chemotherapy after 1990

Cases	Authors	Age (yr)/sex	Type	Site of metastasis	Chemotherapy regimen	Response	Prognosis (mo)
1	Present case	65/F	Recurrent	Liver	EMA/CO	CR	115 NED
2	Waseda et al[5]	68/M	Unresectable	Liver	EP	CR	24 NED
3	Shastri et al[8]	44/M	Unresectable	Liver	BEP	Size reduction	12 DOD
4	Shimuzu et al[9]	43/F	Unresectable	Distant lymph nodes	TS-1/CDDP	Size reduction	7 DOD
5	Yoon et al[10]	62/M	Unresectable	Liver	5-FU/USAN/L-OHP	Progression	16 DOD
					PTX/CDDP	Progression
					5-FU/USAN/CPT-11	Progression
					BEP	Progression
					EMA/CO	Progression
					VIP	Progression
6	Yoon et al[10]	45/M	Unresectable	Liver	BEP	Progression	12 DOD
					VIP	Progression
					EMA/CO	Progression
					5-FU/USAN/CPT-11	Progression
7	Kanemura et al[11]	79/M	Recurrent	No data	TS-1/PTX	Progression	5 DOD
8	Yasumoto et al[12]	76/F	Unresectable	Liver	5-FU	Progression	1 DOD
9	Mori et al[13]	36/F	Recurrent	Brain and lung	EMA/CO	CR	54 NED
10	Enokido et al[14]	54/M	Unresectable	Liver	TS-1	Progression	3 DOD
11	Adachi et al[15]	78/M	Unresectable	Liver	TS-1	CR	12 NED
12	Kishimoto et al[16]	69/M	Recurrent	Liver	Epi-ADM/MMC (TACE)	Progression	17 DOD
					5-FU (HAI)	Progression
					UFT	Progression
13	Kawaguchi et al[17]	60 M	Recurrent	Liver	MTX/BLM/CDDP/CPA	Progression	5 DOD
14	Liu et al[18]	36/F	Unresectable	Colon (infiltration)	BEP	Size reduction	6 DOD
					VBL/IFM/CDDP	Progression
15	Inaki et al[19]	56/M	Recurrent	Liver	MAC (second-line after UFT as adjuvant)	Progression	3 DOD
16	Bayhan et al[20]	26/F	Recurrent	Lung	MAC	Size reduction	18 NED
17	Satoh et al[21]	58/M	Recurrent	Paraaortic lymph nodes	VP-16/CDDP	Progression	6 DOD
18	Kinoshita et al[22]	74/M	Unresectable	Liver	MTX	Progression	3 AWD
19	Imai et al[23]	63/F	Recurrent	Liver	MA	Progression	3 DOD
20	Fujimoto et al[24]	57/M	Recurrent	Liver	MAC	Progression	6 DOD
21	Ogura et al[25]	45/F	Recurrent	Liver	5-FU/MMC/Epi-ADM (HAI)	Size reduction	10 DOD
					VP-16/CDDP	Progression
22	Kan et al[26]	67/M	Unresectable	Liver	5'DFUR/CDDP	Size reduction	10 DOD
					5'DFUR/CDDP/VP-16	Progression
					MTX	Progression
23	Saito et al[27]	57/M	Recurrent	CEA elevation	5-FU/CDDP (second-line after Tegafur as adjuvant)	SD	12 AWD
24	Imatake et al[28]	50/M	Unresectable	Liver	MMC/5-FU/lentinan	Progression	2 DOD
25	Okada et al[29]	57/F	Recurrent	hCG elevation	VAC	Progression	7 DOD
26	Kobayashi et al[30]	60/M	Unresectable	Liver	MTX/ADM (HAI)	Progression	5 DOD
27	Masuda et al[31]	79/M	Unresectable	Liver	UFT	Progression	1.5 DOD

M: Male; F: Female; USAN: Leucovorin; CDDP: Cisplatin; 5-FU: Fluorouracil; L-OHP: Oxaliplatin; CPT-11: Irinotecan; PTX: Paclitaxel; BLM: Bleomycin; CPA: Cyclophosphamide; VBL: Vinblastine; Epi-ADM: Epirubicin; IFM: Ifosfamide; VP-16: Etoposide; 5'DFUR: Doxifluridine; ACT-D: Actinomycin D; ADM: Adriamycin; VCR: Oncovin (vincristine); MMC; Mitomycin C; UFT: Tegafur-uracil; CEA: Carcinoembryonic antigen; β-hCG: β-human chorionic gonadotropin; NED: No evidence of disease; DOD: Died of disease; AWD: Alive with disease; CR: Complete response; SD: Stable disease; TACE: Transcatheter arterial chemoembolization; HAI: Hepatic arterial infusion; EMA/CO: Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine.